Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Sep 01, 2005 (Vol. 25, No. 15)

Recombinomics | Elegant Evolution

URL:www.recombinomics.com
  • Topical information
  • Company focus not clear
As stated on the opening page of the Recombinomics site, “Recombinomics is committed to the study of recombination as the driver of rapid molecular evolution and the emergence of novel infectious agents.” OK, but that doesn’t say what Recombinomics does. Indeed, a good deal of the company’s focus is not apparent. What I was able to gather from poking around extensively was that it exploits recombination to create and evaluate vaccine therapies (one approach). The text at the main site is pretty lacking in content (save for the obvious concerns about bird flu), but I was able to learn quite a bit from the links to online discussion and news programs involving the founder of the site. While I’m still a little hazy on the aims here, they clearly involve evolving viruses and so, with the giant threat posed by bird flu, this site rates at least a mention.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »